First Liquid Biopsy for Neurologic Diseases
18 – 30% of cases of Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease are misdiagnosed.
The FBB Biomed blood test measures newly discovered RNA biomarkers for these neurologic diseases to increase diagnostic accuracy at the time of first diagnosis. This is the world’s first liquid biopsy for neurologic diseases.
The Challenge
Neurologic Misdiagnosis
Our Solution
RNA Biomarkers
Our Product
NGS-based Blood Test
FBB Biomed’s proprietary reagent and bioinformatics software power our blood test based on RNA biomarkers. Our test provides neurologists with a liquid biopsy for the diagnosis of Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease.
Our test runs on standard laboratory sequencing equipment and protocols. No new hardware or processes required.
Actionable Clinical Utility
Use Cases
Early Diagnosis
Is this patient suffering from neurodegeneration?
Differential Diagnosis
Which neurologic disease does this patient have?
Patient Monitoring
How effective has the prescribed therapy been so far?
From the Scientific Community
What Others Say About Us



